Navigation Links
SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
Date:11/17/2009

MUMBAI, India, Nov. 17 /PRNewswire/ -- SIRO Clinpharm, a global Contract Research Organization (CRO) with bases in India, US, Europe and Israel today announced their alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France.

Mediscis is an established expert in GCP compliant early phase drug development services including clinical trials and bioanalytics. SIRO offers expertise across all study phases for the pharmaceutical and biotech industry.

"This will be an important collaboration for both the parties as they stand to gain access to each others' core competencies," said Scott Spector, President, Strategic Operations, Europe. "This alliance will allow us to provide additional services to our global clients to support their clinical development plans."

"Following the acquisition of Omega Mediation Clinical Research Services, SIRO was able to establish a footprint in the European clinical research market. We envision becoming a leading drug development solutions provider by delivering compelling value propositions to the global healthcare industry. From this alliance, we are glad that we can offer a larger array of services to our global clientele and move closer to our vision," said Dr. Chetan Tamhankar, Chief Operating Officer of SIRO Clinpharm.

About SIRO:

SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the Pharmaceutical, Biotechnology and Medical Devices sectors in compliance with International Standards. SIRO is one of the first CROs founded in India and caters to the needs of pharmaceutical companies across the world. The company has offices in India, USA, Israel and in Europe in Germany, Romania, Estonia, Greece and Czech Republic.

For more information visit our website at www.siroclinpharm.com.

SOURCE SIRO Clinpharm


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
2. SIRO Clinpharm and CambReg Ltd Strategic Alliance to Offer Regulatory Services in Europe
3. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
4. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman
8. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Bodycad announced today that it has received ... for its Bodycad Unicompartmental Knee System, enabling the ... Bodycad is the first Canadian company to receive ... Bodycad,s revolutionary Unicompartmental Knee System ... patient,s unique anatomical features and kinematics. The system ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global energy-based aesthetic devices market to grow ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:3/29/2017)... 29, 2017 Global intravenous (IV) iron and oral ... 2021, growing at a CAGR of 5%. ... doctor to treat anemia or other iron deficiencies. Oral iron ... body. However, in some cases, oral administrations are not capable ... (IV) iron therapy comes into the picture. Global ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad ... to eligible individuals in the local community. , Colon cancer is the second ... detect colon cancer while it is small, confined and easier to treat. If you ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever in ... The season for grass pollen runs from May to July each year; with the worst ... to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass ...
(Date:3/29/2017)... ... 29, 2017 , ... Wells Pharmacy Network, a proud A4M ... upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO ... leader in the training of physicians, scientists, and members of the public on ...
(Date:3/29/2017)... WI (PRWEB) , ... March 29, 2017 , ... Dr. ... on early orthodontic treatment and accepting new pediatric patients, with or without a referral. ... young patients have a better orthodontic outcome and experience. When patients receive early treatment, ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor from ... rubber bands used in conjunction with my braces always rubbed against the inside ... way to prevent this problem." The O.B.S. was the result of his brainstorming. ...
Breaking Medicine News(10 mins):